Mydecine Innovations Group Stock Short Ratio

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Based on the latest financial disclosure, Mydecine Innovations Group has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The short ratio for all United States stocks is 100.0% higher than that of the company.

The Macroaxis Fundamental Analysis modules help investors analyze Mydecine Innovations Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mydecine Innovations using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mydecine Innovations Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.